Results 231 to 240 of about 102,860 (309)
A pooled analysis from the prospective UMBRELLA‐IBD registry in Germany (n = 1567) showed comparative real‐world effectiveness in treatment persistence and clinical remission of anti‐TNF, Ustekinumab and Vedolizumab in Crohn's disease patients over 24 months.
Arne Bokemeyer +7 more
wiley +1 more source
Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy
The gut microbiome modulates ulcerative colitis pharmacotherapy through microbial drug metabolism, immune regulation and altered drug bioavailability. Microbial composition influences response to aminosalicylates, corticosteroids, immunomodulators, biologics and small molecules, while microbiome‐targeted therapies show emerging promise.
Kate Collins +6 more
wiley +1 more source
ABSTRACT Background Postpartum health‐related problems are diverse, and some may extend beyond the first postpartum year. The purpose of this study was to describe women's postpartum health problems in the first and second postpartum years. Methods We analyzed data from an online survey (N = 427) conducted in 2024.
Sudhathai Sirithepmontree +2 more
wiley +1 more source
Efficacy of Ustekinumab combined with partial enteral nutrition in Crohn's disease. [PDF]
Yin H +7 more
europepmc +1 more source
Granulomatous Vasculitis: An Unusual Manifestation of Metastatic Crohn’s Disease
Australasian Journal of Dermatology, EarlyView.
Ethan Wei Min Lee +3 more
wiley +1 more source
The potential for biased signalling in the P2Y receptor family of GPCRs
The purinergic receptor family is primarily activated by nucleotides, and contains members of both the G protein coupled‐receptor (GPCR) superfamily (P1 and P2Y) and ligand‐gated ion channels (P2X). The P2Y receptors are widely expressed in the human body, and given the ubiquitous nature of nucleotides, purinergic signalling is involved with a plethora
Claudia M. Sisk +2 more
wiley +1 more source

